321 related articles for article (PubMed ID: 34011158)
1. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
Kuczynski AM; Oh J
Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
[TBL] [Abstract][Full Text] [Related]
2. Ozanimod: First Approval.
Lamb YN
Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
[TBL] [Abstract][Full Text] [Related]
3. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
Rasche L; Paul F
Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
7. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
Fronza M; Lorefice L; Frau J; Cocco E
Drug Des Devel Ther; 2021; 15():1993-2004. PubMed ID: 34007159
[TBL] [Abstract][Full Text] [Related]
8. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
Swallow E; Patterson-Lomba O; Yin L; Mehta R; Pelletier C; Kao D; Sheffield JK; Stonehouse T; Signorovitch J
J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
[No Abstract] [Full Text] [Related]
10. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
13. Ozanimod (Zeposia) for multiple sclerosis.
Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
[TBL] [Abstract][Full Text] [Related]
15. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Chaudhry BZ; Cohen JA; Conway DS
Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
[TBL] [Abstract][Full Text] [Related]
18. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
[TBL] [Abstract][Full Text] [Related]
19. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
Rowan C; Ungaro R; Mehandru S; Colombel JF
Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA; Selmaj KW; Steinman L; Comi G; Bar-Or A; Arnold DL; Hartung HP; Montalbán X; Havrdová EK; Sheffield JK; Minton N; Cheng CY; Silva D; Kappos L; Cohen JA
Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]